Back to Cell Types

BFTC-909Homo sapiens (Human)Cancer cell line

Also known as: Black Foot disease Transitional Carcinoma 909, BFTC909, BFTC 909

🤖 AI SummaryBased on 11 publications

Quick Overview

Human renal cell carcinoma cell line with known genetic mutations.

Detailed Summary

The BFTC-909 cell line is a human renal cell carcinoma (RCC) cell line derived from a renal pelvis tumor. It is widely used in cancer research due to its specific genetic characteristics, including mutations in key oncogenes and tumor suppressor genes. This cell line has been extensively studied for its role in understanding the molecular mechanisms of RCC, particularly in relation to genomic instability and drug resistance. Research on BFTC-909 has contributed to the identification of potential therapeutic targets and biomarkers for RCC. The cell line is also utilized in studies involving the analysis of copy number variations and gene expression profiles to better understand tumor progression and response to treatment.

Research Applications

Genomic instability studiesDrug resistance mechanismsTherapeutic target identificationCopy number variation analysisGene expression profiling

Key Characteristics

Mutations in key oncogenesGenomic instabilityDrug resistance traitsCopy number variations

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1084
Species	Homo sapiens (Human)
Tissue Source	Kidney, renal pelvis[UBERON:UBERON_0001224]

Donor Information

Age	64
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Upper tract urothelial carcinoma
Lineage	Kidney
Subtype	Renal Cell Carcinoma
OncoTree Code	RCC

DepMap Information

Source Type	DSMZ
Source ID	ACH-000792_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Ser241Cys (c.722C>G)	Homozygous	-	PubMed=30737244, PubMed=29846633
MutationSimple	TERT	c.1-124C>T (c.228C>T) (C228T)	Unspecified	In promoter	from parent cell line Hep-G2
Gene fusion	CNGB1	KIFC3-CNGB1	-	-	from parent cell line BFTC-909

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12,13

D13S317

11,13

D16S539

9,10

D18S51

13

D19S433

13

D21S11

28,29

D2S1338

23,24

D3S1358

15

D5S818

11,12

D7S820

12

D8S1179

13,15

FGA

24,25.2

Penta D

9,11

Penta E

12,23

TH01

7

TPOX

8

vWA

14,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.

Hsieh J.J.-D., Hakimi A.A.

Nat. Commun. 8:15165.1-15165.10(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

Androgen receptor decreases the cytotoxic effects of chemotherapeutic drugs in upper urinary tract urothelial carcinoma cells.

Chang C.-S.

Oncol. Lett. 5:1325-1330(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan.

Lin J.S.

Anticancer Res. 16:1797-1804(1996).